A Randomized Phase 3 Study of Nivolumab Plus Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin in Subjects With Unresectable Advanced, Recurrent or Metastatic Previously Untreated Esophageal Squamous Cell Carcinoma

Trial Profile

A Randomized Phase 3 Study of Nivolumab Plus Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin in Subjects With Unresectable Advanced, Recurrent or Metastatic Previously Untreated Esophageal Squamous Cell Carcinoma

Recruiting
Phase of Trial: Phase III

Latest Information Update: 17 Dec 2017

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Cisplatin; Fluorouracil
  • Indications Oesophageal cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Acronyms CheckMate 648
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 01 Sep 2017 Planned End Date changed from 29 Jun 2021 to 30 Dec 2021.
    • 01 Sep 2017 Planned End Date changed from 29 Jun 2021 to 30 Dec 2021.
    • 10 Jul 2017 Planned end date changed from 15 Jun 2021 to 29 Jun 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top